Donald Trump plans to impose up to 200% tariffs on imported pharmaceuticals to cut foreign dependence.

The Commerce Department is probing national security risks from overseas drug production.

Industry Reaction:

Drugmakers warn of shortages and reduced patient access. PhRMA says the move will hurt investment in US innovation.

India’s Impact:

India’s $8.95B pharma exports to the US may suffer. Major firms like Dr. Reddy’s and Zydus face margin pressure, increased US competition, and calls for export diversification amid broader economic strain.